Breast CarcinomaCancerLungs and breathing
What this study is
This study collects information on the side effects of proton therapy and detailed information on the proton therapy treatment plan itself. This may help researchers develop methods to predict the risk of side effects for future patients and learn the long-term benefit of proton therapy.
What's being tested
- Quality-of-Life Assessment
Intervention · OTHER
- Questionnaire Administration
Intervention · OTHER
Both interventions
Complete questionnaires
Study details
- Official title
- Data Collection to Assess Acute and Late Normal Tissue Sequelae in Proton Therapy for Adults
- Sponsor
- M.D. Anderson Cancer Center
- Conditions
- Breast Carcinoma · Esophageal Carcinoma · Genitourinary System Carcinoma · Head and Neck Carcinoma · Hematopoietic and Lymphoid Cell Neoplasm · Lung Carcinoma · Malignant Central Nervous System Neoplasm · Malignant Digestive System Neoplasm · Malignant Solid Neoplasm
- Enrolling
- 5,000 people
- Starts
- 2005-05-27
- Est. completion
- 2027-12-31
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- All patients scheduled for radiation treatment with protons at UTMDACC are eligible for this protocol
- Patients must sign a study-specific consent form prior to study entry
You can't join if
- Patients who are unable or unwilling to attend the required periodic follow-ups either at M.D. Anderson or at a different site
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (1)
1 openM D Anderson Cancer Center
Houston, Texas, United States
- Steven J. Frank · Contact713-563-2300
- Steven J. Frank · Principal investigator
Recruiting
Study team
Sponsor
M.D. Anderson Cancer Center
Study ID PCR05-0207
Principal investigator
Steven J Frank
M.D. Anderson Cancer Center
Have questions? The contacts above can answer them before you apply.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.